Is SLNO or SLS more undervalued in 2026?

CirclFi compares Soleno Therapeutics, Inc. (SLNO) and SELLAS Life Sciences Group, Inc (SLS) using 13 institutional-grade valuation models. SLNO has a Quality of Company score of 7.1/10 while SLS scores 4.1/10.

Which is a better buy — SLNO or SLS?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do SLNO and SLS valuations compare?

SLNO at $53.01 and SLS at $9.18 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

SLNO vs SLS Valuation Comparison 2026 — Intrinsic Value Analysis

SLNO

Biotechnology

Soleno Therapeutics, Inc.

Quality

7.1

out of 10

Value Trap

SAFE

Price

$53.01

Last close

Models

13/13

Active

SLS

Biotechnology

SELLAS Life Sciences Group, Inc

Quality

4.1

out of 10

Value Trap

SAFE

Price

$9.18

Last close

Models

7/13

Active

Model-by-Model Comparison

Model	Type	SLNO Fair Value	SLNO Upside	SLS Fair Value	SLS Upside
Bayesian DCF	Intrinsic	$13.39	-74.7%	$2.78	-69.8%
Earnings Power Value	Intrinsic	$2.73	-94.8%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$6.44	-87.8%	$0.65	-92.9%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for SLNO vs SLS — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

SLNO vs SLS — Which Stock Is More Undervalued?

SLNO scores higher with a 7.1/10 quality rating vs SLS's 4.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Soleno Therapeutics, Inc. (SLNO) and SELLAS Life Sciences Group, Inc (SLS) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

SLNO currently trades at $53.01 with a QOC of 7.1/10, while SLS trades at $9.18 with a QOC of 4.1/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).